Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 02, 2023 16:01 ET | Source: Invivyd

Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
October 31, 2023 16:01 ET | Source: Invivyd

Invivyd to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
September 11, 2023 07:00 ET | Source: Invivyd

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
September 06, 2023 07:00 ET | Source: Invivyd

Invivyd to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
September 05, 2023 07:00 ET | Source: Invivyd

Invivyd Appoints William Duke as Chief Financial Officer

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
August 10, 2023 16:01 ET | Source: Invivyd

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

Reported positive initial Phase 1 VYD222 clinical trial data, including favorable safety data and robust serum neutralizing titers from all three dose levels testedPlans to pursue rapid initiation of...
August 03, 2023 16:01 ET | Source: Invivyd

Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
July 27, 2023 16:01 ET | Source: Invivyd

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

WALTHAM, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
July 17, 2023 07:00 ET | Source: Invivyd

Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

Continued favorable safety and tolerability profile for all dose levels testedSerum samples from all dose levels tested showed robust neutralization activity against Omicron XBB.1.5, one of the...
June 26, 2023 07:00 ET | Source: Invivyd

Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

Unique, rapid development pathway for monoclonal antibodies (mAbs) using immunobridging via serum neutralizing titers could be enabled by previously generated clinical trial data from prototype...